Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$76.35
+0.7%
$68.38
$60.47
$76.80
$236.72B0.476.67 million shs9.03 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$43.99
+0.7%
$50.37
$43.33
$69.10
$89.17B0.4514.31 million shs12.10 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$734.97
-2.8%
$761.06
$419.80
$800.78
$698.52B0.372.63 million shs4.60 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.73%+1.57%+14.28%+16.32%+2.36%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+0.66%-1.94%-15.71%-9.69%-33.99%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.77%+0.20%-5.33%+10.08%+70.45%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
1.5771 of 5 stars
1.33.01.70.01.90.03.1
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9495 of 5 stars
4.14.02.54.02.91.71.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.7157 of 5 stars
2.43.02.54.02.61.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.57
Moderate Buy$81.006.09% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0036.39% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$757.953.13% Upside

Current Analyst Ratings

Latest LLY, AZN, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/26/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/16/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B5.17$5.43 per share14.05$12.10 per share6.31
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B1.98$12.53 per share3.51$8.16 per share5.39
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.47$7.41 per share99.12$13.57 per share54.16

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$2.0437.4316.381.3813.30%30.42%11.62%7/26/2024 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B-$3.10N/A6.2414.72-13.50%8.83%2.50%7/25/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$6.79108.2439.451.5017.08%56.98%10.94%8/13/2024 (Estimated)

Latest LLY, AZN, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
2/8/202412/31/2023
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.74$0.73-$0.01$1.15$12.07 billion$12.02 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.53%+1.18%94.61%1 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.46%+8.20%N/A N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%76.58%10 Years

Latest LLY, AZN, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
2/8/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Semi-Annual$0.96502.3%2/22/20242/23/20243/25/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.73
0.89
0.70
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.99
1.11
0.99
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.90
1.35
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.03 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.41 million949.17 millionOptionable

LLY, AZN, and BMY Headlines

SourceHeadline
National Bank of Canada FI Cuts Stock Holdings in Eli Lilly and Company (NYSE:LLY)National Bank of Canada FI Cuts Stock Holdings in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 4 at 4:34 PM
Dont Wait for Fed to Cut Rates. Profit Now!Don't Wait for Fed to Cut Rates. Profit Now!
investorplace.com - May 4 at 12:00 PM
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the MakingMove Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
fool.com - May 4 at 8:30 AM
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
fool.com - May 4 at 5:26 AM
Q3 2024 Earnings Forecast for Eli Lilly and Company Issued By Leerink Partnrs (NYSE:LLY)Q3 2024 Earnings Forecast for Eli Lilly and Company Issued By Leerink Partnrs (NYSE:LLY)
americanbankingnews.com - May 4 at 3:24 AM
Goldstream Capital Management Ltd Acquires 3,729 Shares of Eli Lilly and Company (NYSE:LLY)Goldstream Capital Management Ltd Acquires 3,729 Shares of Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 4 at 12:36 AM
Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
finance.yahoo.com - May 3 at 11:29 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 3.2% Eli Lilly and Company (NYSE:LLY) Shares Down 3.2%
marketbeat.com - May 3 at 9:55 PM
Eli Lilly Remains Expensive Here - Minimal Margin Of SafetyEli Lilly Remains Expensive Here - Minimal Margin Of Safety
seekingalpha.com - May 3 at 4:00 PM
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slideAmgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
cnbc.com - May 3 at 10:44 AM
MarketBeat Week in Review – 4/22 - 4/26 (LLY)MarketBeat Week in Review – 4/22 - 4/26 (LLY)
marketbeat.com - May 3 at 10:17 AM
Eli Lilly and Company Expected to Post Q3 2024 Earnings of $3.75 Per Share (NYSE:LLY)Eli Lilly and Company Expected to Post Q3 2024 Earnings of $3.75 Per Share (NYSE:LLY)
marketbeat.com - May 3 at 9:17 AM
Eli Lilly: Dont Overpay For Miracle DrugsEli Lilly: Don't Overpay For Miracle Drugs
seekingalpha.com - May 3 at 6:12 AM
Eli Lilly and Company (NYSE:LLY) PT Raised to $892.00 at Truist FinancialEli Lilly and Company (NYSE:LLY) PT Raised to $892.00 at Truist Financial
americanbankingnews.com - May 3 at 6:04 AM
Eli Lilly and Company (NYSE:LLY) PT Raised to $1,001.00Eli Lilly and Company (NYSE:LLY) PT Raised to $1,001.00
americanbankingnews.com - May 3 at 5:32 AM
Q2 2024 EPS Estimates for Eli Lilly and Company Reduced by Analyst (NYSE:LLY)Q2 2024 EPS Estimates for Eli Lilly and Company Reduced by Analyst (NYSE:LLY)
americanbankingnews.com - May 3 at 2:24 AM
Eli Lilly and Company (NYSE:LLY) Stake Increased by Fifth Third BancorpEli Lilly and Company (NYSE:LLY) Stake Increased by Fifth Third Bancorp
marketbeat.com - May 3 at 12:32 AM
Eli Lilly and Company (NYSE:LLY) Just Released Its First-Quarter Earnings: Heres What Analysts ThinkEli Lilly and Company (NYSE:LLY) Just Released Its First-Quarter Earnings: Here's What Analysts Think
finance.yahoo.com - May 2 at 8:05 PM
Analysts reveal Eli Lilly stock price targets after earningsAnalysts reveal Eli Lilly stock price targets after earnings
msn.com - May 2 at 8:05 PM
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?
fool.com - May 2 at 7:23 PM
Earnings Season: 3 Companies Boosting GuidanceEarnings Season: 3 Companies Boosting Guidance
zacks.com - May 2 at 4:01 PM
Novo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.Novo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.
finance.yahoo.com - May 2 at 3:04 PM
Eli Lilly and Company (NYSE:LLY) Trading Down 1.2%Eli Lilly and Company (NYSE:LLY) Trading Down 1.2%
marketbeat.com - May 2 at 2:47 PM
Despite 350% Rally, Novo Trades at Discount to Eli LillyDespite 350% Rally, Novo Trades at Discount to Eli Lilly
quiverquant.com - May 2 at 1:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.